MedTrace Logo

A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19

NCT05172141 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 222

Last updated 2023-03-01

No results posted yet for this study

Summary

This is a Phase 1/2 study evaluating the safety, tolerability and efficacy of IBI314.

Conditions

Interventions

BIOLOGICAL

IBI314(low dose)

intravenously, once, on Day 1

BIOLOGICAL

IBI314(high dose)

intravenously, once, on Day 1

BIOLOGICAL

IBI314(medium dose)

intravenously, once, on Day 1

OTHER

Placebo

intravenously, once, on Day 1

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-31
Primary Completion
2022-08-31
Completion
2023-01-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05172141 on ClinicalTrials.gov